MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6370
-0.0246
-3.72%
After Hours: 0.6300 -0.007 -1.10% 16:07 07/14 EDT
OPEN
0.6600
PREV CLOSE
0.6616
HIGH
0.6600
LOW
0.6001
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
2.770
52 WEEK LOW
0.4850
MARKET CAP
91.07M
P/E (TTM)
-0.4880
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBRV stock price target is 1.750 with a high estimate of 2.000 and a low estimate of 1.500.

EPS

NBRV News

More
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 07/01 14:05
Peacock adds Vizio, LG as launch partners
Seeking Alpha - Article · 06/24 18:53
Walt Disney World employees petition to delay reopening as coronavirus cases surge in Florida
As the number of coronavirus cases surge in Florida, more than 7,000 people have signed an online petition urging Disney and government officials to reconsidering the opening of Disney World next month.
CNBC.com · 06/24 15:53
Comcast gets pair of target hikes, noting broadband upside
Seeking Alpha - Article · 06/24 15:32
CONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says Analyst
SmarterAnalyst · 06/24 02:12
NBCUniversal, Google sign Peacock distribution deal
Seeking Alpha - Article · 06/23 18:48
CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/23 18:32
Is Nabriva Therapeutics plc (NBRV) A Good Stock To Buy?
Insider Monkey · 06/22 20:23

Industry

Biotechnology & Medical Research
+2.52%
Pharmaceuticals & Medical Research
+1.64%

Hot Stocks

Symbol
Price
%Change

About NBRV

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
More

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.